Erwinaze is associate injectable drugs containing antineoplastic drug enterics chrysanthemi. antineoplastic drugcould be a cancer medication that interferes with the expansion and unfold of cancer cells within the body.
Erwinaze is employed to treat acute leukocyte cancer.
Erwinaze might also be used for different functions unlisted during this medication guide.
Submit your review
Get emergency medical help if you have any signs of an allergic reaction to Erwinaze: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
any bleeding that will not stop;
sudden numbness or weakness, especially on one side of the body;
sudden severe headache, confusion, problems with vision, speech, or balance;
chest pain, sudden cough, wheezing, rapid breathing, coughing up blood;
pain, swelling, warmth, or redness in one or both legs; or
high blood sugar (increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, weight loss).
Less serious Erwinaze side effects may include:
mild stomach pain.
The recommended dose for each planned dose of pegaspargase is 25,000 International Units/m2 administered intramuscularly or intravenously three times a week (Monday/Wednesday/Friday) for six doses. To substitute for a dose of native E. coli asparaginase: The recommended dose is 25,000 International Units/m2administered intramuscularly or intravenously for each scheduled dose of native E. coli asparaginase within a treatment. When administering ERWINAZE intravenously, consider monitoring nadir (pre-dose) serum asparaginase activity (NSAA) levels and switching to intramuscular administration if desired NSAA levels are not achieved.